HCA
APLS

Harbor Capital Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Harbor Capital Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,303
Closed -$392K – 455
2023
Q2 		$392K Sell
4,303
-68
-2% -$5.87K 0.08% 287
2023
Q1 		$288K Sell
4,371
-88
-2% -$5.08K 0.08% 190
2022
Q4 		$2.31M Buy
+4,459
New +$237K 2.24% 13

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbor Capital Advisors's APLS Position: Q3 2023 in Review

Harbor Capital Advisors sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 4,303 shares — an estimated $392K sold.

Harbor Capital Advisors first reported a position in APLS in Q4 2022 and held it in 3 quarters. The position peaked at $2.31M in Q4 2022. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Harbor Capital Advisors reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Harbor Capital Advisors sold 4,303 Apellis Pharmaceuticals shares in Q3 2023, an estimated $392K.
  • Harbor Capital Advisors first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Harbor Capital Advisors's Apellis Pharmaceuticals position peaked at $2.31M in Q4 2022.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Harbor Capital Advisors's 13F filing for Q3 2023, filed 20 Oct 2023.